文献

重组抗人HLA-DR单克隆抗体(克隆号L243) ，小鼠IgG2a Kappa（Recombinant Anti-human HLA-DR Monoclonal Antibody (Clone: L243), Mouse IgG2a Kappa，货号：PA007464.m2a Syd Labs）

人类主要组织相容性复合体II类分子（HLA Class II）中的HLA-DR是一种高度多态性的跨膜异二聚体糖蛋白，主要表达于树突状细胞、B细胞、单核/巨噬细胞等专业抗原提呈细胞（APC）以及活化的T细胞和NK细胞表面。HLA-DR在提呈外源性肽抗原给CD4+ helper T细胞并引发适应性免疫应答中扮演核心角色。经典克隆号L243单克隆抗体能够特异性识别HLA-DR分子的α/β二聚体构象依赖性表位，且不依赖于所绑定的肽段序列。抗人HLA-DR单抗（L243抗体）被广泛应用于多色流式细胞术分选及表型分析、抗原提呈细胞功能测定、混合淋巴细胞反应（MLR）阻断，以及免疫排斥反应、自身免疫性疾病和肿瘤免疫微环境的相关机制研究。

Syd Labs推出的重组抗人HLA-DR单抗（L243抗体）采用先进的哺乳动物表达系统重组合成，克服了传统杂交瘤培养带来的批间差异与抗体漂移问题，保障了卓越的批次间一致性与高亲和力。该产品按体内实验级（In Vivo Grade）标准严格精制，具备极低内毒素（Low Endotoxin）水平且不含任何防腐剂，有效规避了体外敏感细胞培养及体内动物模型中的细胞毒性与非特异性干扰。采用标准的Mouse IgG2a Kappa结构，Syd Labs L243抗体可与配套同型对照结合使用，为免疫学、肿瘤学及药物开发研究提供严谨可靠、高重复性的实验数据支持。

抗人HLA-DR单抗(L243)部分参考文献:

1. Identifying major histocompatibility complex class II-DR molecules in bovine and swine peripheral blood monocyte-derived macrophages using mAb-L243
class=”reference-item”>Celis-Giraldo, C., et al. Vaccine. 2024 May 31;42(14):3319-3329. doi: 10.1016/j.vaccine.2024.04.032
“The L243 monoclonal antibody (anti-human HLA-DR) was used to identify MHC-II-DR molecules in bovine and swine macrophages via flow cytometry, mass spectrometry, and immunopurification. The study demonstrated cross-reactivity of L243 with bovine and swine DR class II molecules, validating its use for immunopeptidomics to identify Staphylococcus aureus and Salmonella enterica peptides presented by MHC-II-DR.”

2. HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway
Aljabri, A., et al. Cell Death Dis. 2019 Mar 8;10(3):235. doi: 10.1038/s41419-019-1482-z
“The L243 antibody (anti-human HLA-DR) induced cell death in IFN-γ-stimulated human endothelial cells after 3 hours, as shown by annexin V/propidium iodide and LIVE/DEAD staining. Preincubation with soluble recombinant HLA-DR confirmed L243’s specific binding to HLA-DR, demonstrating its cytotoxic effect in the absence of complement, unlike its proliferative effect after 48 hours.”

3. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20–243 CrossMab
Zhao, L., et al. MAbs. 2014 May-Jun;6(3):740-8. doi: 10.4161/mabs.28424
“The L243 antibody (anti-human HLA-DR) served as a positive control for HLA-DR binding in flow cytometry, showing comparable binding affinity to CD20-243 CrossMab on Raji cells. L243 competition confirmed specific HLA-DR epitope binding, with flow cytometry revealing enhanced internalization upon co-engagement of CD20 and HLA-DR.”

4. A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope
Kobayashi, H., et al. Cancer Immunol Immunother. 2012 Dec;61(12):2201-9. doi: 10.1007/s00262-012-1282-3
“The L243 antibody (anti-human HLA-DR) was used to immunoprecipitate HLA-DR molecules from HTLV-1-transformed T cells, with eluted peptides analyzed by mass spectrometry. Flow cytometry with L243 confirmed high HLA-DR surface expression, and L243 blocked T cell responses, verifying HLA-DR-restricted presentation of an IL-9 receptor alpha epitope.”

5. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
Stein, R., et al. Blood. 2006 Oct 15;108(8):2736-44. doi: 10.1182/blood-2006-03-010389
“The L243 antibody (anti-human HLA-DR), among other murine anti-HLA class II mAbs, demonstrated antibody-dependent cellular cytotoxicity (ADCC) in lymphoma cells. A humanized IgG4 version of L243 retained direct antilymphoma activity without effector functions, enhancing rituximab’s potency in targeting HLA-DR-expressing cells.”